Penn Center for Innovation

Parker Institute for Cancer Immunotherapy

Posted on April 13, 2016 — Kat Hinkel

Penn is a founding partner of the Parker Institute for Cancer Immunotherapy, which unites six of the nation’s top medical schools and cancer centers around the shared aim of accelerating breakthroughs in cures for cancer through immunotherapy approaches.  The effort is backed by as much as $250 million in support from the Parker Foundation, making it the largest single contribution ever made to the field of immunotherapy.

The Parker Institute’s Director at Penn will be Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Pathology and Laboratory Medicine department of the Perelman School of Medicine, and director of Translational Research in the Abramson Cancer Center. Robert Vonderheide, MD, DPhil, the Hanna Wise Professor in Cancer Research and associate director of translational research in the Abramson Cancer Center, and John Wherry, PhD, a professor of Microbiology and director of Penn’s Institute for Immunology, will serve as co-directors.
Penn Press Release
Fortune

Category: